Brill | Nijhoff
Brill | Wageningen Academic
Brill Germany / Austria
Brill | Fink
Brill | mentis
Brill | Schöningh
Vandenhoeck & Ruprecht
How to publish with Brill: Files & Guides
Fonts, Scripts and Unicode
Publication Ethics & COPE Compliance
Data Sharing Policy
Ordering from Brill
Piracy Reporting Form
Catalogs, Flyers and Price Lists
E-Book Collections Title Lists and MARC Records
How to Manage your Online Holdings
Sales Managers and Sales Contacts
Ordering From Brill
LibLynx Access Management
Online User and Order Help
Titles No Longer Published by Brill
Latest Key Figures
Latest Financial Press Releases and Reports
Annual General Meeting of Shareholders
Open Access for Authors
Open Access and Research Funding
Open Access for Librarians
Open Access for Academic Societies
Discover Brill’s Open Access Content
Corporate Social Responsiblity
Policies, rights & permissions
Review a Brill Book
Rights and Permissions
Press and Reviews
Stay informed about this journal!
Get access to the full article by using one of the access options below.
Buy instant access (PDF download and unlimited online access):
Other access options
Log in with Open Athens, Shibboleth, or your institutional credentials
Log in with your brill.com account
L.A. Barrera and G.C. Galindo, ‘Ethical aspects on rare diseases’, Adv Exp Med Biol 686 (2010) 493-511.
J.E. Davies, S. Neidle and D.G. Taylor, ‘Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?’, Br J Cancer 106(1) (2012) 14-17.
G.S. Ginsburg and J.J. McCarthy, ‘Personalized medicine: revolutionizing drug discovery and patient care’, Trends in Biotechnology 19(12) (2001) 491-496.
M. Herder, ‘When everyone is an orphan: Against adopting a US-styled orphan drug policy in Canada’, Accountability in Research-Policies and Quality Assurance 20(4) (2013) 227-269.
A. Montserrat Moliner and J. Waligora, ‘The European union policy in the field of rare diseases’, Public Health Genomics 16(6) (2013) 268-277.
A. Paturel, ‘Too Rare for Research? People with rare diseases often experience significant delays in diagnosis and access to few, if any, treatment options’, Neurology Now 8(2) (2012) 29-33.
Humanities Matter Blog
Across the Rainbow
Survival by Degrees
War and Peace
Primary source collections
How to publish with Brill
Open Access Content
Contact & Info
Social Media Overview
Terms and Conditions
Terms and Conditions | Privacy Statement | Cookie Settings | Accessibility | Legal Notice
Copyright © 2016-2023
Character limit 500/500